Supplementary Data from Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma

Autor: William Wachsman, Mark A. Dickson, Ronald Mitsuyasu, David Aboulafia, Robert J. Gorelick, Frank Maldarelli, Richard F. Ambinder, Dirk P. Dittmer, Shelly Y. Lensing, Adrienne Suazo, Erin G. Reid
Rok vydání: 2023
Popis: Supplementary Methods and Figure Supplemental Figure 1. Images demonstrating improvement in KS lesions in two patients obtaining partial response to bortezomib despite receiving treatment in the lowest 2 dose cohorts. Both patients met criteria for partial response after 2 cycles of bortezomib. A. Images for "Patient 2" (dose level 1) demonstrate fading of lesion pigmentation after cycle 2 and further fading after cycle 8; less well-appreciable from photographs is the observed flattening of initially raised lesions. B. After only 2 cycles of bortezomib, "Patient 5" (dose level 2) experienced resolution of several lesions and fading of others.
Databáze: OpenAIRE